Table 2 Multivariate Cox proportional hazard regression analysis for progression-free survival (PFS) and overall survival (OS) according to pre-treatment peripheral lymphocyte count.
PFS | OS | |||
|---|---|---|---|---|
aHR (95% CI) | P | aHR (95% CI) | P | |
Age, years | ||||
< 65 | 1 (reference) | 1 (reference) | ||
65–74 | 0.57 (0.35, 0.94) | 0.03 | 0.71 (0.42, 1.19) | 0.19 |
≥ 75 | 0.56 (0.32, 0.97) | 0.04 | 0.7 (0.38, 1.28) | 0.25 |
Sex | ||||
Male | 1 (reference) | 1 (reference) | 0.58 | |
Female | 1.14 (0.68, 1.91) | 0.41 | 1.1 (0.63, 1.89) | |
Smoking status | 0.75 | |||
Never | 1 (reference) | 1 (reference) | ||
Ever | 0.59 (0.35, 1.02) | 0.04 | 0.85 (0.47, 1.52) | |
ECOG (ref 0) | ||||
0 | 1 (reference) | 1 (reference) | ||
1 | 1.54 (0.85, 2.81) | 0.18 | 1.93 (0.96, 3.91) | 0.12 |
≥ 2 | 2.37 (1.25, 4.51) | 0.01 | 3.61 (1.78, 7.32) | 0.001 |
Histology | ||||
Adenocarinoma | 1 (reference) | 1 (reference) | ||
Squamous cell carcinoma | 1.14 (0.59, 2.20) | 0.63 | 1.00 (0.49, 2.03) | 0.86 |
Other NSCLC | 1.41 (0.83, 2.38) | 0.32 | 2.02 (1.19, 3.42) | 0.01 |
EGFR activating mutation | 3.24 (1.80, 5.82) | < 0.001 | 1.90 (0.99, 3.66) | 0.10 |
PD-L1 expression (≥ 1%) | 0.43 (0.27, 0.69) | 0.001 | 0.47 (0.28, 0.77) | 0.002 |
Pre-treatment PLC Quartile [25th-75th] | ||||
1 [144.2–1041.9] | 1 (reference) | 1 (reference) | ||
2 [1059.1–1524.4] | 0.68 (0.40, 1.17) | 0.26 | 0.53 (0.3, 0.93) | 0.004 |
3 [1527.5–2070] | 0.37 (0.20, 0.70) | 0.004 | 0.25 (0.12, 0.51) | < 0.001 |
4 [2081.3–6241] | 0.40 (0.23, 0.71) | 0.002 | 0.36 (0.2, 0.66) | 0.002 |
P for trend | 0.006 | 0.035 | ||
